Description: Direxion mRNA ETF is an exchange traded fund launched by Direxion Investments. The fund is managed by Rafferty Asset Management, LLC. It invests in public equity markets of global region. The fund invests in stocks of companies operating across development and application of messenger RNA or the mRNA technology sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track the performance of the BITA Messenger RNA Technology Index, by using full replication technique. Direxion mRNA ETF is domiciled in the United States.
Exchange: NYSE ARCA
Country: US
Currency: US Dollar ($)
Category: Health
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 78.67 | 0.00 | 78.67 |
| Stock non-US | 21.36 | 0.00 | 21.36 |
| Cash | 0.00 | 0.02 | -0.02 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 100.00 | 99.57 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 78.65 | 92.60 |
| Europe Developed | 12.86 | 4.28 |
| Asia Emerging | 8.50 | 0.82 |
| Japan | 0.00 | 0.54 |
| Australasia | 0.00 | 0.11 |
| United Kingdom | 0.00 | 1.65 |
| Africa/Middle East | 0.00 | 0.02 |